Clinical Pharmacokinetics

, Volume 45, Issue 7, pp 745–754 | Cite as

Comparison of Oxycodone Pharmacokinetics after Buccal and Sublingual Administration in Children

  • Hannu Kokki
  • Ilpo Rasanen
  • Merja Lasalmi
  • Sanna Lehtola
  • Veli-Pekka Ranta
  • Kari Vanamo
  • Ilkka Ojanperä
Original Research Article

Abstract

Objective

We evaluated and compared the pharmacokinetics of two oral administration routes of oxycodone parenteral liquid (10 mg/mL) - single buccal and sublingual administration - in 30 generally healthy awake children, aged 6–91 months.

Methods

Two groups of children undergoing inpatient surgery were enrolled. In a randomised fashion, children received a single dose of oxycodone 0.2 mg/kg buccally (n = 15) or sublingually (n = 15). Regular blood samples were collected for up to 12 hours, and plasma was analysed for oxycodone, oxymorphone and noroxycodone using gas chromatography-mass spectrometry.

Results

Bioavailability was similar after administration at the two instillation sites. The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC) was 2400–8000 ng · min/mL (median 4200 ng · min/mL) in the buccal group and 2700-7900 ng · min/mL (median 5500 ng · min/mL) in the sublingual group. After buccal administration, maximum plasma concentration (Cmax) was 5.4–39 ng/mL (16 ng/mL) after buccal and 5.5–42 ng/mL (22 ng/mL) after sublingual administration. Twelve of the 15 children in both groups reached the oxycodone analgesic concentration of 12 ng/mL, which was sustained for 43–209 minutes (median 160 minutes) in the children with buccal oxycodone and for 32–262 minutes (median 175 minutes) in the children with sublingual oxycodone. The terminal elimination half-lives were closely similar in the two groups: 104–251 minutes (median 140 minutes) in the buccal group and 110–190 minutes (150 minutes) in the sublingual group.

Conclusion

The results of this study show that in young children the absorption of oxycodone is similar after buccal and sublingual instillation.

References

  1. 1.
    Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005; 59: 674–6PubMedCrossRefGoogle Scholar
  2. 2.
    Freund M, Speyer E. Uber die Umwandlung von Thebain in Oxycodeinon und dessen Derivate. J Prak Chemie 1916; 153/94: 135–78CrossRefGoogle Scholar
  3. 3.
    Falk E. Eukodal. Ein neues Narkotikum. Munch Med Wochenschr 1917; 20: 381–4Google Scholar
  4. 4.
    Kalso E. Oxycodone. J Pain Symptom Manage 2005; 29 (5 Suppl.): S47–56PubMedCrossRefGoogle Scholar
  5. 5.
    Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998; 1: 15–30PubMedGoogle Scholar
  6. 6.
    Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 1992; 81: 1–10PubMedCrossRefGoogle Scholar
  7. 7.
    Kokki H, Rasanen I, Reinikainen M, et al. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinet 2004; 43: 613–22PubMedCrossRefGoogle Scholar
  8. 8.
    Kokki H, Lintula H, Vanamo K, et al. Oxycodone vs placebo in children with undifferentiated abdominal pain: a randomized, double-blind clinical trial of the effect of analgesia on diagnostic accuracy. Arch Pediatr Adolesc Med 2005; 159: 320–5PubMedCrossRefGoogle Scholar
  9. 9.
    Broussard LA, Presley LC, Pittman T, et al. Simultaneous identification and quantitation of codeine, morphine, hydrocodone, and hydromorphone in urine as trimethylsilyl and oxime derivatives by gas chromatography-mass spectrometry. Clin Chem 1997; 43: 1029–32PubMedGoogle Scholar
  10. 10.
    Cremece M, Wu AHB, Gassella G, et al. Improved GC/MS analysis of opiates with use of oxime-TMS derivatives. J Forensic Sci 1998; 43: 1220–4Google Scholar
  11. 11.
    Ropero-Miller JD, Lambing MK, Winecker RE. Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization. J Anal Toxicol 2002; 26: 524–8PubMedGoogle Scholar
  12. 12.
    Jones J, Tomlinson K, Moore C. The simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, 6-acetylmorphine, and oxycodone in hair and oral fluid. J Anal Toxicol 2002; 26: 171–5PubMedGoogle Scholar
  13. 13.
    Huber L. Validation of analytical methods: review and strategy. LC-GC Int 1998; 11: 96–105Google Scholar
  14. 14.
    Tuomilehto H, Kokki H, Ahonen R, et al. Postoperative behavioral changes in children after adenoidectomy. Arch Otolaryngol Head Neck Surg 2002; 128: 1159–64PubMedGoogle Scholar
  15. 15.
    Peters JW, Koot HM, de Boer JB, et al. Major surgery within the first 3 months of life and subsequent biobehavioral pain responses to immunization at later age: a case comparison study. Pediatrics 2003; 111: 129–35PubMedCrossRefGoogle Scholar
  16. 16.
    McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 9481: 205–10CrossRefGoogle Scholar
  17. 17.
    Olkkola KT, Hamunen K, Seppälä T, et al. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol 1994; 38: 71–6PubMedCrossRefGoogle Scholar
  18. 18.
    Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 44: 335–42PubMedCrossRefGoogle Scholar
  19. 19.
    Takala A, Kaasalainen V, Seppälä T, et al. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand 1997; 41: 309–12PubMedCrossRefGoogle Scholar
  20. 20.
    Pokela ML, Anttila E, Seppälä T, et al. Marked variation in oxycodone pharmacokinetics in infants. Paediatr Anaesth 2005; 7: 560–5CrossRefGoogle Scholar
  21. 21.
    Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokineticpharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59: 52–61PubMedCrossRefGoogle Scholar
  22. 22.
    Leow KP, Smith MT. The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 1994; 54: 1229–36PubMedCrossRefGoogle Scholar
  23. 23.
    Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32: 447–54PubMedCrossRefGoogle Scholar
  24. 24.
    Chen ZR, Irvine RJ, Somogyi AA, et al. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48: 2165–71PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Hannu Kokki
    • 1
    • 2
  • Ilpo Rasanen
    • 3
  • Merja Lasalmi
    • 1
  • Sanna Lehtola
    • 2
  • Veli-Pekka Ranta
    • 4
  • Kari Vanamo
    • 5
  • Ilkka Ojanperä
    • 3
  1. 1.Department of Anaesthesiology and Intensive CareKuopio University HospitalKuopioFinland
  2. 2.Department of Pharmacology and ToxicologyUniversity of KuopioKuopioFinland
  3. 3.Department of Forensic MedicineUniversity of HelsinkiHelsinkiFinland
  4. 4.Department of PharmaceuticsUniversity of KuopioKuopioFinland
  5. 5.Department of SurgeryKuopio University HospitalKuopioFinland

Personalised recommendations